Britain’s pharma trade body has issued a fresh Brexit warning, saying it would be disadvantageous to both the UK and the EU if drugs regulation diverges as a result of the political changes.
The UK pharmaceutical industry has paid the Department of Health £190 million during the first two quarters of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).